SCM
THRD

Suvretta Capital Management’s Third Harmonic Bio THRD Stock Holding History

Suvretta Capital Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,000
Closed -$3.79M – 106
2022
Q3 		$3.79M Buy
+200,000
New +$3.6M 0.16% 61

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Suvretta Capital Management's THRD Position: Q4 2022 in Review

Suvretta Capital Management sold out of Third Harmonic Bio (THRD) in Q4 2022, closing a stake of 200,000 shares — an estimated $3.79M sold.

Suvretta Capital Management first reported a position in THRD in Q3 2022 and held it in 1 quarter. The position peaked at $3.79M in Q3 2022. 50 funds tracked by Wall St. Rank hold THRD as of Q4 2022.

  • Suvretta Capital Management reported no remaining Third Harmonic Bio position as of Q4 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 200,000 Third Harmonic Bio shares in Q4 2022, an estimated $3.79M.
  • Suvretta Capital Management first reported a position in Third Harmonic Bio in Q3 2022 and held it in 1 quarter.
  • Suvretta Capital Management's Third Harmonic Bio position peaked at $3.79M in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.